Cell Therapeutics to submit supplemental filing for Zevalin

09/22/2008 | MarketWatch

Cell Therapeutics is planning to submit later this year a supplemental Biologics License Application that proposes a label expansion for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The company, following a meeting with the FDA, said the First-Line Indolent Trial results of Zevalin are sufficient to support the sBLA.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC